Evidence map›Paper›PMID 34795257›Full record

ArticleNature communications2021

Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation.

Grigory Ryzhakov, Hannah Almuttaqi, Alastair L Corbin, Dorothée L Berthold, Tariq Khoyratty, Hayley L Eames, Samuel Bullers, Claire Pearson, Zhichao Ai, Kristina Zec and 6 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. MiR-222-3p Aggravates the Inflammatory Response by Targeting SOCS1 to Activate STAT3 Signaling in Ulcerative Colitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Grigory Ryzhakov *University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.
Hannah Almuttaqi *University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.
Alastair L CorbinUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.ORCID http://orcid.org/0000-0001-7308-9286
Dorothée L BertholdUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-9045-6348
Tariq KhoyrattyUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.ORCID http://orcid.org/0000-0001-5911-0026
Hayley L EamesUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.
Samuel BullersUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.
Claire PearsonUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.
Zhichao AiUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.
Kristina ZecUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.
Sarah BonhamTarget Discovery Institute, Nuffield Department of Medicine, Centre for Medicines Discovery, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, United Kingdom.
Roman FischerTarget Discovery Institute, Nuffield Department of Medicine, Centre for Medicines Discovery, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-9715-5951
Luke Jostins-DeanUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-2475-3969
Simon P L TravisTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-2690-4361
Benedikt M KesslerTarget Discovery Institute, Nuffield Department of Medicine, Centre for Medicines Discovery, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-8160-2446
Irina A UdalovaUniversity of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom. irina.udalova@kennedy.ox.ac.uk.ORCID http://orcid.org/0000-0002-6716-2528
University of Oxford · GBChinese Academy of Medical Sciences & Peking Union Medical College · CNJohn Radcliffe Hospital · GBNovartis (Switzerland) · CH

Funding

Versus Arthritis 20966Versus Arthritis 209966Wellcome Trust 208750/Z/17/Z
6 · The paper itself

Abstract

Interferon regulating factor 5 (IRF5) is a multifunctional regulator of immune responses, and has a key pathogenic function in gut inflammation, but how IRF5 is modulated is still unclear. Having performed a kinase inhibitor library screening in macrophages, here we identify protein-tyrosine kinase 2-beta (PTK2B/PYK2) as a putative IRF5 kinase. PYK2-deficient macrophages display impaired endogenous IRF5 activation, leading to reduction of inflammatory gene expression. Meanwhile, a PYK2 inhibitor, defactinib, has a similar effect on IRF5 activation in vitro, and induces a transcriptomic signature in macrophages similar to that caused by IRF5 deficiency. Finally, defactinib reduces pro-inflammatory cytokines in human colon biopsies from patients with ulcerative colitis, as well as in a mouse colitis model. Our results thus implicate a function of PYK2 in regulating the inflammatory response in the gut via the IRF5 innate sensing pathway, thereby opening opportunities for related therapeutic interventions for inflammatory bowel diseases and other inflammatory conditions.

Indexed as

AnimalsBenzamidesCells, CulturedColitisCytokinesFocal Adhesion Kinase 2Gene Expression ProfilingHEK293 CellsHumansInflammationInterferon Regulatory FactorsIntestinesMacrophagesMaleMiceMice, Inbred C57BLBenzamidesCytokinesdefactinibFocal Adhesion Kinase 2Interferon Regulatory FactorsIrf5 protein, mousePtk2b protein, mousePyrazinesSulfonamides

Identifiers

PMID34795257
PMCPMC8602323
OpenAlexW3212851218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.